Navigation Links
Entest BioMedical Files 3rd Patent Application for COPD Stem Cell Treatment
Date:11/18/2009

New Patent Application covers technology to re-direct auto-immune related inflammation

San Diego (PRWEB) November 18, 2009 -- Entest BioMedical Inc. (OTCBB: ENTB) announced today the filing of a third patent application relating to the area of chronic obstructive pulmonary disease (COPD), a condition that affects more than 5 million patients in the United States, resulting in more than 120,000 deaths per year. The application covers an implantable medical device useful in re-directing the immune system to stop tissue inflammation.

“The importance of the inflammatory process in COPD is exemplified by the use of broad-acting steroids that reduce inflammation. Unfortunately, these drugs do not address the cause of the inflammation, and have a variety of adverse effects” Stated Dr. Stephen Josephs, inventor of the technology.

A recent article “Immunologic aspects of chronic obstructive pulmonary disease” by Cosio et al in the June 4th, 2009 issue of New England Medical Journal suggests that COPD may actually be not just a disease of inflammation but, of active immunological attack. The current technology seeks to induce a process in which immunity towards components of the body is blocked.

“To date Entest has filed two previous patent applications covering use of fat stem cell components in COPD and methods of using photoceuticals to enhance stem cell therapy. The current patent application has a variety of derivative uses outside of COPD including treatment of transplantation rejection, and other disease in which the immune system has gone awry” Stated David Koos, Entest’s CEO.

The essence of the technology is the use of existing implantable devices to deliver chemical/protein signals that specifically stop inflammatory reactions in a manner that is more in tune with biological processes. Instead of us “telling the body” what it should do with a blunt-force approach, as is the standard of care, the current invention uses more natural and slow acting interventions.

About Entest BioMedical Inc.:
Entest BioMedical Inc. (OTCBB: ENTB) is a majority owned subsidiary of Bio-Matrix Scientific Group Inc (OTCBB: BMSN). The Company is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), immuno-cancer therapies, testing procedures for diabetes, stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation).

Disclaimer
This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Contact:

David R. Koos, Chairman & CEO
619.702.1404 Direct
619.330.2328 Fax

Entest BioMedical Inc.
www.EntestBio.com

###

Read the full story at http://www.prweb.com/releases/chronic_obstructive/pulmonary_disease/prweb3225544.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Bio-Matrix Scientific Group and Entest BioMedical Sign Contract With UCLA Researcher to Develop Gestational Diabetes Screening Test
2. Entest BioMedical Inc. Adds Former National Cancer Institute Researcher to Scientific Advisory Board With Focus on Stem Cell Cancer Patient Therapies
3. Entest BioMedical, Inc. Discusses How Therapies in Development May Yield Lucrative Revenue Streams for the Company
4. Response Biomedical appoints S. Wayne Kay Chief Executive Officer
5. Hopes, Predictions and Realities: Is Biomedical Research Delivering On Its Promises?
6. Dr. Andrew K. Palmer Joins BMEs (BioMedical Enterprises, Inc.) Board of Directors
7. BME (BioMedical Enterprises, Inc.) Announces U.S. Launch of the OSSArc(TM) Anatomic Residual Compression Implant
8. Response Biomedical Corporation Receives Conditional Listing Approval from the Toronto Stock Exchange
9. XCPT(TM) Patient Engagement and Communication Software Signs Representation Agreement with Lifecore Biomedical, Inc. (Nasdaq: LCBM)
10. American Red Cross Announces New Leader for Biomedical Services
11. New nanotube findings by Stanford researchers give boost to potential biomedical applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... 24, 2017 , ... The results from the American Cancer Society’s ... for prostate cancer patients: incidents of cancer is down as is the likelihood of ... death rate has dropped from its peak of 215.1 in 1991 to 161.2 in ...
(Date:1/24/2017)... ... ... American Family Care (AFC) has opened a new 4,000+ square foot state-of-the-art urgent ... area. The Bedford clinic will be the nineteenth location opened by AFC in Massachusetts ... Dr. Kristina Orio. Adams and Orio also independently own and operate AFC clinics in ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... natural supplement for relieving premenstrual syndrome, or PMS . , Most women ... These symptoms can include cramps, constipation, irritability, headaches, fatigue, and other discomfort. ...
(Date:1/24/2017)... ... ... Would Have Dreamed: A Novel of Miracles”: a beautiful and poignant glimpse into the ... in her life. “Who Would Have Dreamed: A Novel of Miracles” is the creation of ... , Sharon shares that she started her spiritual journey later in life, but ...
(Date:1/24/2017)... ... January 24, 2017 , ... “The Octagon of Spiritual Balances”: a ... Balances” is the creation of published author, Pastor Bernard J. Weathers, pastor of Word ... bachelor degree in religious education and a master degree in theology. , ““The Octagon ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... , Jan. 23, 2017 Research and Markets ... - Forecast to 2021" report to their offering. ... The interventional radiology products ... USD 6.35 Billion in 2016, at a CAGR of 4.8%. This ... The major factors driving the growth of this market are ...
(Date:1/23/2017)... , Jan. 23, 2017 7D ... 510(k) clearance from the U.S. Food and Drug ... Health Canada enabling the North American commercial launch ... system for spine surgery, the 7D Surgical System.  ... cutting-edge 3D optical technologies and machine vision algorithms ...
(Date:1/23/2017)... -- The American Pharmacists Association (APhA) is excited about ... Underserved Areas Enhancement Act (H.R. 592) in ... previously introduced in the 114 th session of ... pharmacists and their patient care services. Sponsors ... (R-KY), G.K. Butterfield (D-NC), Tom Reed ...
Breaking Medicine Technology: